Other Events ·
FDA grants minor-use status for CannEpil, opening conditional approval pathway for canine bone cancer pain treatment
EDVAEndovia Health Sciences, Inc.
The U.S. Food and Drug Administration determined that Endovia Health Sciences' investigational cannabinoid oral solution, CannEpil®, qualifies as a minor use for controlling pain associated with bone cancer in dogs under the Minor Use and Minor Species program. This status establishes eligibility for the conditional approval pathway, allowing commercialization while additional effectiveness data is collected post-approval. The company plans to meet with the FDA on November 19, 2026, for a Pre-Submission Conference to align on development requirements and is finalizing U.S.-based manufacturing capabilities to support a potential veterinary launch in 2027. Endovia Health Sciences operates as a cannabinoid health sciences company focused on pharmaceutical development and FDA-regulated therapeutics.